Literature DB >> 10408602

Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study.

O K Hassani1, J Féger.   

Abstract

Subthalamic neuronal activity is controlled by a dopaminergic innervation, which may act via D1 and D2 dopamine receptors. This study investigates the effect of apomorphine and the selective D1 and D2 agonists, SKF 82958 and quinpirole respectively, in normal and 6-hydroxydopamine-lesioned rats. The effect of microinjection of these drugs into the subthalamic nucleus was assessed by recording unit activity and the expression of the c-Fos-immunoreactive protein in the subthalamic nucleus. Dopaminergic agonists reduced the discharge rate and did not induce c-Fos expression in the normal rat. Apomorphine and quinpirole increased the discharge rate and induced a strong expression of c-Fos-like immunoreactive proteins, whereas SKF 82958 induced a decrease of the discharge rate and a slight expression of c-Fos in 6-hydroxydopamine-lesioned rats. The striking contrast in the changes obtained with apomorphine and quinpirole in normal and 6-hydroxydopamine-lesioned rats is discussed in relation to a hyperexpression of D2 dopaminergic receptors on the GABAergic terminals into the subthalamic nucleus. These results show that, in normal rats, dopamine agonists exert an inhibitory control on subthalamic neurons via D1 and D2 receptors. However, in 6-hydroxydopamine-lesioned rats, the hyperactivity of subthalamic neurons is also reduced by D1 receptor agonist but not by D2 dopamine agonists. This last result points out one aspect of the complex mechanisms underlying the physiopathology of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408602     DOI: 10.1016/s0306-4522(98)00765-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  16 in total

1.  Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro.

Authors:  K Z Shen; S W Johnson
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

2.  Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.

Authors:  Adriana Galvan; Xing Hu; Karen S Rommelfanger; Jean-Francois Pare; Zafar U Khan; Yoland Smith; Thomas Wichmann
Journal:  J Neurophysiol       Date:  2014-04-23       Impact factor: 2.714

3.  Intrinsic dynamics and synaptic inputs control the activity patterns of subthalamic nucleus neurons in health and in Parkinson's disease.

Authors:  C J Wilson; M D Bevan
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

4.  Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Abraham Mathai; Yuxian Ma; Jean-Francois Paré; Rosa M Villalba; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2015-02-12       Impact factor: 13.501

5.  Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.

Authors:  T R K Varma; S H Fox; P R Eldridge; P Littlechild; P Byrne; A Forster; A Marshall; H Cameron; K McIver; N Fletcher; M Steiger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

6.  The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.

Authors:  M Lagière; S Navailles; L Mignon; A Roumegous; M-F Chesselet; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-03-28       Impact factor: 1.972

7.  D5 (not D1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance.

Authors:  Jérôme Baufreton; Maurice Garret; Alicia Rivera; Adélaïda de la Calle; François Gonon; Bernard Dufy; Bernard Bioulac; Anne Taupignon
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

8.  Extrastriatal dopaminergic circuits of the Basal Ganglia.

Authors:  Karen S Rommelfanger; Thomas Wichmann
Journal:  Front Neuroanat       Date:  2010-10-27       Impact factor: 3.856

9.  The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson's disease.

Authors:  Jian Cao; Jian Liu; Qiao-Jun Zhang; Tao Wang; Shuang Wang; Ling-Na Han; Qiang Li
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

Review 10.  The T-type calcium channel as a new therapeutic target for Parkinson's disease.

Authors:  Ya-Chin Yang; Chun-Hwei Tai; Ming-Kai Pan; Chung-Chin Kuo
Journal:  Pflugers Arch       Date:  2014-02-18       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.